Harvey Alan Jacobs
Pharmacy in Dallas, PA
License number
Utah 147066-8911
Issued Date
Apr 20, 1990
Expiration Date
Dec 31, 1992
Category
Pharmacy
Type
Pharmacist Controlled Substance
Address
Address
Dallas, PA
Professional information
Targeting Of Peg Antibody Conjugates To Islet Cells
US Patent:
2001001, Aug 2, 2001
Filed:
Dec 29, 1998
Appl. No.:
09/222357
Inventors:
HARVEY JACOBS - DALLAS PA, US
SUNG WAN KIM - SALT LAKE CITY UT, US
VIRGINIE MENARD - SALT LAKE CITY UT, US
SUNG WAN KIM - SALT LAKE CITY UT, US
VIRGINIE MENARD - SALT LAKE CITY UT, US
International Classification:
A61K039/395, A61K039/40, A61K039/42, A61K039/44
US Classification:
424/178100, 424/141100, 424/180100
Abstract:
A method for delaying onset of insulin dependent diabetes mellitus (IDDM) in an individual predisposed to developing the disease is disclosed. The method comprises administering a composition comprising an immunologically effective monoclonal antibody or fragment thereof against glutamic acid decarboxylase (GAD) coupled to a nonimmunogenic hydrophilic polymer that provides a hydration shell around the monoclonal antibody for inhibiting immune recognition thereof. Poly(ethylene glycol) is a preferred polymer. A method of reducing insulitis in an IDDM patient and a composition therefor are also described.
Targeting Of Peg Antibody Conjugates To Islet Cells
US Patent:
5853723, Dec 29, 1998
Filed:
Sep 20, 1996
Appl. No.:
8/710653
Inventors:
Harvey Jacobs - Dallas PA
Sung Wan Kim - Salt Lake City UT
Virginie Menard - Salt Lake City UT
Sung Wan Kim - Salt Lake City UT
Virginie Menard - Salt Lake City UT
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A61K 39395, A61K 3944, A61K 4700
US Classification:
4241781
Abstract:
A method for delaying onset of insulin dependent diabetes mellitus (IDDM) in an individual predisposed to developing the disease is disclosed. The method comprises administering a composition comprising an immunologically effective monoclonal antibody or fragment thereof against glutamic acid decarboxylase (GAD) coupled to a nonimmunogenic hydrophilic polymer that provides a hydration shell around the monoclonal antibody for inhibiting immune recognition thereof. Poly(ethylene glycol) is a preferred polymer. A method of reducing insulitis in an IDDM patient and a composition therefor are also described.